

SERVICES PORTFOLIO



CONTACT US AT:

PANGAEA ONCOLOGY
Laboratorio de Oncología
Hospital Universitari Dexeus
Consultas Externas. Despacho -1.7
C/Sabino de Arana 5-19,
08028 Barcelona

Samples and assays:

+34 935 460 119
+34 935 460 121

lab@panoncology.com
www.panoncology.com



MARCH 2024

MOLECULAR TESTING OF TUMOR TISSUE SAMPLES

NUCLEIC ACID EXTRACTION

PP-T-001	Macrodissection and DNA extraction from FFPE tissue
PP-T-002	Macrodissection and RNA extraction from FFPE tissue

COMBINED STUDIES

CS-T-001	<p>SOLID TUMOR (<i>Recommended for LUNG, MELANOMA, BREAST and other Solid tumors</i>)</p> <p>CS-T-001</p> <p>NGS Somatic QIaseq DNA Custom Extended Panel (30 genes) Genes: <i>ALK, ARID1A, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FAT1, FGFR1, FGFR2, FGFR3, IDH1, IDH2, KEAP1, KIT, KRAS, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, POLD1, POLE, RET, ROS1, SETD2, STK11, TP53</i></p> <p>nCounter RNA Fusion and Gene Expression Tumor Panel* Fusions: <i>ALK, FGFR1,2,3, NRG1, NTRK1,2,3, RET, ROS1</i> Splicing variant: <i>EGFRvIII, METΔ14</i> Gene expression analysis: <i>ALK, ATM, BARD1, BID, BRCA1, BRCA2, CCNE1, CD274, CD4, CD8A, CDK2, EGFR, FGFR1,2,3, FOXP3, GZMM, IFNG, KRAS, NRG1, NTRK1,2,3, PDCD1, PTEN, RET, ROS1, STK11, TP53</i></p>
CS-T-002	<p>CS-T-002</p> <p>Combined study CS-T-001 and PD-L1 IHC</p>

**The nCounter RNA Pangaea Solid Tumor Panel could be replaced by the NGS RNA Fusion XP Lung Panel (ask for prices)*

CS-T-003	<p>UROTHELIAL carcinoma study</p> <p>CS-T-003</p> <p>NGS Somatic QIaseq DNA Custom Extended Panel (30 genes) nCounter RNA Fusion Urothelial Carcinoma Panel Fusions: <i>FGFR2 and FGFR3</i> Identification of the variants: <i>FGFR2-BICC1, FGFR2-CASP7, FGFR3ex17-TACC3ex10</i> <i>FGFR3ex17-TACCex11, FGFR3-BAIAP2L1</i></p>
CS-T-004	<p>COLON study</p> <p>CS-T-004</p> <p>KRAS, BRAF, NRAS sequencing (NGS Custom Panel) (19 genes) Genes: <i>ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FGFR1, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, STK11, TP53</i></p> <p>Mismatch Repair (MMR) status (IHC) Genes: <i>MLH1, MSH2, MSH6, PMS2</i></p>
MS-T-001	<p>GIST study</p> <p>c-KIT, PDGFR sequencing (NGS Custom Panel) (19 genes)</p>

— MULTIGENIC MOLECULAR PANELS

MS-T-002	NGS somatic QIAsq DNA Breast-Gynecological custom Panel (11 genes) Genes: <i>AKT, BRCA1, BRCA2, CTNNB1, ERBB2, ESR1, PALB2, PIK3CA, POLE, PTEN, TP53</i>
MS-T-003	NGS Somatic QIAsq DNA Custom Extended Panel (30 genes) Genes: <i>ALK, ARID1A, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FAT1, FGFR1, FGFR2, FGFR3, IDH1, IDH2, KEAP1, KIT, KRAS, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, POLD1, POLE, RET, ROS1, SETD2, STK11, TP53</i>
MS-T-004	NGS RNA Fusion XP Lung Panel (13 genes) Fusions: <i>ALK, BRAF, EGFR, FGFR1,2,3, MET, NRG1, NTRK1,2,3, RET, ROS1</i> Splicing variant: <i>METΔ14</i>
MS-T-005	NGS Somatic QIAsq DNA Repair Genes Panel (28 genes) Genes: <i>APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CTNNB1, EPCAM, FANCA, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, STK11, TP53</i>
MS-T-006	nCounter RNA Fusion and Gene expression Tumor Panel Fusions: <i>ALK, FGFR1,2,3, NRG1, NTRK1,2,3, RET, ROS1</i> Splicing variants: <i>EGFRvIII, METΔ14</i> Gene expression analysis: <i>ALK, ATM, BARD1, BID, BRCA1, BRCA2, CCNE1, CD274, CD4, CD8A, CDK2, EGFR, FGFR1,2,3, FOXP3, GZMM, IFNG, KRAS, NRG1, NTRK1,2,3, PDCD1, PTEN, RET, ROS1, STK11, TP53</i>
MS-T-007	nCounter RNA Pangaea Urothelial Carcinoma Panel Fusions: <i>FGFR2 and FGFR3</i> Identification of the variants: <i>FGFR2-BICC1, FGFR2-CASP7, FGFR3ex17-TACC3ex10, FGFR3ex17-TACCex11, FGFR3-BAIAP2L1</i>
MS-T-008	PROSIGNA Genetic prognostic signature for breast cancer

— INDIVIDUAL GENE MUTATIONS (TaqMan® allelic discrimination qPCR assay)

ISM-T-001	One hotspot mutation (<i>BRAF, EGFR, KRAS, PIK3CA</i>)
ISM-T-002	<i>EGFR</i> exon 19 del and <i>EGFR</i> exon 21 (L858R, L861Q) mutations
ISM-T-003	<i>EGFR</i> exon 19 de, <i>EGFR</i> exon 21 (L858R, L861Q) and <i>EGFR</i> exon 20 T790M mutations
ISM-T-004	<i>EGFR</i> exon 20 resistance mutation T790M
ISM-T-005	<i>EGFR</i> exon 20 resistance mutation C797S
ISM-T-006	<i>KRAS</i> hotspot mutations (codons 12, 13 and 61)
ISM-T-007	<i>BRAF</i> hotspot mutations (V600E, V600K, V600R)
ISM-T-008	<i>PIK3CA</i> hotspot mutations (codons 542, 545 and 1047)
ISM-T-009	<i>ESR1</i> hotspot mutations (codons 380, 536, 537, 538)

— SPlicing VARIANTS AND FUSIONS (nCounter Technology)

IST-T-001	Fusion variant or <i>MET</i> splicing variant single analysis Fusions: <i>ALK, FGFR1,2,3, NRG1, NTRK1,2,3, RET, ROS1</i> Splicing variants: <i>EGFRvIII, METΔ1</i>
-----------	---

ANATOMIC PATHOLOGY

— ANATOMICAL PATHOLOGY DIAGNOSIS

PP-T-003	Anatomical pathology diagnosis (H&E and 4 IHC analysis)
PP-T-004	Confirmation of anatomical pathology diagnosis (Previous AP report required)

— MAIN FISH ASSAYS*

ISF-T-001	HER-2/neu amplification**
ISF-T-002	<i>ALK</i> fusions**
ISF-T-003	<i>ROS1</i> fusions
ISF-T-004	<i>RET</i> fusions
ISF-T-005	<i>MET</i> amplification
ISF-T-006	<i>EGFR</i> amplification
ISF-T-007	<i>KRAS</i> amplification
ISF-T-008	<i>NTRK1</i> fusions
ISF-T-009	<i>NTRK2</i> fusions
ISF-T-010	<i>NTRK3</i> fusions
ISF-T-011	<i>FGFR1</i> fusions
ISF-T-012	<i>FGFR1</i> amplification

ISF-T-013	FGFR2 fusions
ISF-T-014	FGFR2 amplification
ISF-T-015	FGFR3 fusions
ISF-T-016	FGFR3 amplification
ISF-T-017	BCL2 fusions
ISF-T-018	BCL6 fusions
ISF-T-019	NRG1 fusions
ISF-T-020	MYC fusions
ISF-T-021	MYC amplification
ISF-T-022	1p/19q loss

* Ask for other IHC or FISH assays if required

** FDA approved

— MAIN PRONOSTIC AND PREDICTIVE IMMUNOHISTOCHEMISTRY (IHC) ASSAYS*

ISI-T-001	ALK (D5F3) **
ISI-T-002	PDL1 (22C3)
ISI-T-003	Mismatch Repair (MMR) status (MLH1, MSH2, MSH6, PMS2)
ISI-T-004	MET (SP44)
ISI-T-005	BRG1 (SMARCA4) (E8V5B)
ISI-T-006	ERBB2 (4B5)

* Ask for other IHC or FISH assays if required

** FDA approved

EXTERNALIZED SERVICES

PO-E-001	ONCOPDO 3D Organoid Test (Invitrocue)
PO-E-002	Oncotype DX
PO-E-003	Foundation ONE CDx

MOLECULAR TESTING OF TUMOR LIQUID BIOPSY SAMPLES

NUCLEIC ACID EXTRACTION

PP-BL-001	cfDNA extraction from liquid biopsies
PP-BL-002	cfRNA extraction from liquid biopsies
PP-LB-003	DNA extraction from white blood cells

COMBINED STUDIES

CS-BL-001	<p>CS-BL-001 (Recommended for all type of tumors) NGS Somatic QIAseq DNA Custom Panel (19 genes) Genes: <i>ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FGFR1, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, STK11, TP53</i></p> <p>nCounter RNA Fusion Solid Tumor Panel for liquid biopsies (6 genes) *Fusions: <i>ALK, NRG1, NTRK1, RET, ROS1</i> Splicing variants: <i>METΔ14</i> *More frequently found fusions</p>
-----------	--

MULTIGENIC MOLECULAR PANELS

MS-BL-001	<p>NGS Somatic QIAseq DNA Custom Panel (19 genes) Genes: <i>ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FGFR1, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, STK11, TP53</i></p>
MS-BL-002	<p>NGS Somatic QIAseq DNA Custom Extended Panel (30 genes) Genes: <i>ALK, ARID1A, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FAT1, FGFR1, FGFR2, FGFR3, IDH1, IDH2, KEAP1, KIT, KRAS, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, POLD1, POLE, RET, ROS1, SETD2, STK11, TP53</i></p>
MS-BL-003	<p>nCounter RNA Pangaea Solid Tumor Panel for Liquid Biopsies (6 genes) *Fusions: <i>ALK, NRG1, NTRK1, RET, ROS1</i> Splicing variants: <i>METΔ14</i> *More frequently fusions</p>
MS-BL-004	<p>NGS somatic QIAseq DNA Breast-Gynecological custom Panel (11 genes) Genes: <i>AKT, CTNNB1, ERBB2, ESR1, PALB2, PIK3CA, POLE, PTEN, TP53</i></p>

— INDIVIDUAL GENE MUTATIONS (TaqMan® allelic discrimination qPCR assay)

ISM-BL-001	One hotspot mutation (<i>EGFR</i> , <i>KRAS</i> , <i>BRAF</i> , <i>PIK3CA</i>)
ISM-BL-002	<i>EGFR</i> exon 19 del and <i>EGFR</i> exon 21 (L858R, L861Q) mutations
ISM-BL-003	<i>EGFR</i> exon 19 del, <i>EGFR</i> exon 21 (L858R, L861Q) and <i>EGFR</i> exon 20 T790M mutations
ISM-BL-004	<i>EGFR</i> exon 20 resistance mutation T790M
ISM-BL-005	<i>EGFR</i> exon 20 resistance mutation C797S
ISM-BL-006	<i>KRAS</i> hotspot mutations (codons 12, 13 and 61)
ISM-BL-007	<i>BRAF</i> hotspot mutations (V600E, V600K, V600R)
ISM-BL-008	<i>PIK3CA</i> hotspot mutations (codons 542, 545 and 1047)
ISM-BL-009	<i>ESR1</i> hotspot mutations (codons 380, 536, 537, 538)

— SPLICING VARIANTS AND FUSIONS (nCounter Technology)

IST-BL-001	Fusion variant or <i>MET</i> splicing variant single analysis Fusions: <i>ALK</i> , <i>NRG1</i> , <i>NTRK1</i> , <i>RET</i> , <i>ROS1</i> Splicing variants: <i>MET</i> Δ14
------------	--

**GERMLINE MOLECULAR
TESTING ASSOCIATED
WITH INHERITED
PREDISPOSITION
SYNDROMES**

MULTIGENIC MOLECULAR PANELS

MS-G-001	<p>NGS QIAseq Inherited Cancer Panel (28 genes, germline)</p> <p>Genes: <i>APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCA, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, STK11, TP53</i></p>
-----------------	--

INMUNOHISTOCHEMISTRY (IHC) ASSAYS (Recommended for Lynch syndrome)

ISI-T-003	<p>Mismatch Repair (MMR) status (<i>MLH1, MSH2, MSH6, PMS2</i>)*</p>
------------------	---

**Sample required: FFPE Block*

MOLECULAR TESTING FOR OPHTHALMOLOGICAL DISEASES

MULTIGENIC MOLECULAR PANELS

OF-BL-001	<p>nCounter Gene Expression Lacrima Dx (24 genes)</p> <p>Genes: <i>B2M, CCL4, CD46, CFB, CTSS, GAPDH, HLA-A, HLA-DMB, HLA-DRB3, IFITM1, IRF7, JAK1, LGALS3, MUC1, MX1, MYD88, OAZ1, PSMB8, RARRES3, SERPING1, STAT1, STAT2, TAP1, TAPBP</i></p>
OF-BL-002	<p>nCounter Gene Expression Lacrima Extended Dx (96 genes)</p> <p>Genes: <i>ABCf1, ADA, AHR, ALAS1, ARHGDI1B, ATG5, B2M, BAX, BCAP31, BCL10, C14orf166, CASP3, CCL4, CCND3, CCRL1, CD14, CD19, CD46, CD59, CD83, CD99, CEACAM6, CFB, CFH, CFI, CTNNA1, CTSC, CTSS, CXCR2, DUSP4, EEF1G, FADD, FKBP5, G6PD, GAPDH, GUSB, HLA-A, HLA-C, HLA-DMB, HLA-DPA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HPRT1, IFI16, IFI35, IFITM1, IFNAR1, IFNG, IKZF2, IKBKG, IL13RA1, IL32, IL6ST, IL8, IRF5, IRF7, JAK1, LGALS3, LTF, MAPK1, MUC1, MX1, MYD88, NFKB1, NFKBIA, OAZ1, PIGR, PLA2G2A, PLA2, PML, POLR1B, POLR2A, PPIA, PSMB10, PSMB5, PSMB7, PSMB8, PTK2, PYCARD, RARRES3, RUNX1, S100A9, SDHA, SERPING1, SLC2A1, SMAD3, STAT1, STAT2, TAP1, TAPBP, TBP, TUBB</i></p>

EXTERNAL SERVICES

PO-E-004	<p>CentoVision Panel (Inherited Diseases)</p>
----------	--

SERVICES PORTFOLIO




CONTACT US AT:

PANGAEA ONCOLOGY
Laboratorio de Oncología
Hospital Universitari Dexeus
Consultas Externas. Despacho -1.7
C/Sabino de Arana 5-19,
08028 Barcelona

Samples and assays:

+ 34 935 460 119
+ 34 935 460 121

lab@panoncology.com
www.panoncology.com



MARCH 2024